Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,284Revenue $M115Net Margin (%)--Altman Z-Score--
Enterprise Value $M3,284EPS $-0.3Operating Margin %--Piotroski F-Score--
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M194ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with AVNR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AVNRMario Gabelli 2014-12-31 Buy 0.04%$10.92 - $17.01
($14.08)
$ 16.9620%New holding493,524
AVNRLeon Cooperman 2014-09-30 Buy 0.02%$5.18 - $12.49
($6.76)
$ 16.96151%New holding100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AVNR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


AVNR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OCAMPO CHRISTINEVice President, Finance 2014-12-18Sell35,780$16.940.12view
Siffert Joao MDSVP, R&D 2014-12-18Sell15,505$16.930.18view
Katkin KeithPresident and CEO 2014-12-17Sell277,680$16.950.06view
PALEKAR ROHANSVP & Chief Commercial Officer 2014-11-28Sell15,000$1513.07view
Katkin KeithPresident and CEO 2014-10-24Sell27,567$11.7644.22view
OCAMPO CHRISTINEVice President, Finance 2014-10-24Sell2,080$11.8143.61view
Siffert Joao MDSVP, R&D 2014-10-24Sell8,426$11.843.73view
PALEKAR ROHANSVP & Chief Commercial Officer 2014-09-15Sell25,000$11.547.48view
OCAMPO CHRISTINEVice President, Finance 2014-09-15Sell55,000$9.4579.47view
OCAMPO CHRISTINEVice President, Finance 2014-08-26Sell2,110$6.1178.03view

Quarterly/Annual Reports about AVNR:

    News about AVNR:

    Articles On GuruFocus.com
    Gabelli's Q4 Picks Include Acquisition Targets Feb 06 2015 
    A Look at Leon Cooperman's Most Performing Recent Buys Jan 30 2015 
    Weekly CEO Sells Highlight: Danaher Corporation, Orbitz Worldwide Inc., 3D Systems Corporation and A May 20 2013 
    Weekly CEO Sells Highlight: Universal Insurance Holdings Inc, Avanir Pharmaceuticals Inc, Bel Fuse I Jun 30 2012 
    Options V: Short-Term Strategy – Earning Money on Volatility Oct 19 2011 
    Avanir Pharmaceuticals Reports Operating Results (10-Q) Feb 07 2011 
    Avanir Pharmaceuticals Reports Operating Results (10-K) Dec 08 2010 
    Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 195,300 Shares Dec 03 2010 
    Weekly CEO Sells Highlights: MAC, GNET, ASIA, and AVNR Sep 05 2010 
    Avanir Pharmaceuticals (AVNR) President and CEO Keith Katkin sells 102,874 Shares Sep 02 2010 

    More From Other Websites
    Avanir Pharmaceuticals Announces FDA Approval of ONZETRA™ Xsail™ (AVP-825) for the Acute... Jan 28 2016
    Avanir Pharmaceuticals Announces Appointment of Rohan Palekar as President and Chief Executive... Jan 20 2016
    Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients... Dec 10 2015
    Avanir Pharmaceuticals Announces Publication of Study Evaluating the Prevalence of Pseudobulbar... Dec 01 2015
    Concert Pharmaceuticals Achieves $2 Million Milestone from Avanir Pharmaceuticals for Phase 3... Nov 16 2015
    Avanir Pharmaceuticals Announces Initiation of Phase III Trial of AVP-786 for Agitation in Patients... Nov 16 2015
    Avanir Pharmaceuticals Announces JAMA Publication of Phase II Study Results Showing AVP-923... Sep 22 2015
    Avanir Pharmaceuticals Announces JAMA Publication of Phase II Study Results Showing AVP-923... Sep 22 2015
    Avanir Pharmaceuticals Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026 Aug 11 2015
    Avanir Pharmaceuticals Prevails in NUEDEXTA® Patent Appeal Maintaining Exclusivity Through 2026 Aug 11 2015
    Avanir Pharmaceuticals Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II... Jul 23 2015
    Avanir Pharmaceuticals Announces New Findings from Dementia/Alzheimer's Disease Cohort of PRISM II... Jul 23 2015
    /C O R R E C T I O N -- Avanir Pharmaceuticals, Inc./ Jun 30 2015
    /C O R R E C T I O N -- Avanir Pharmaceuticals, Inc./ Jun 30 2015
    Avanir Pharmaceuticals Announces Positive Top-line Results from Stroke and TBI Cohorts of PRISM II... Jun 30 2015
    Avanir Pharmaceuticals Announces Publication of Positive Phase IIIb Results from AVP-825... Jun 17 2015
    Avanir Pharmaceuticals Announces Publication of Positive Phase IIIb Results from AVP-825... Jun 17 2015
    Avanir Pharmaceuticals Announces Presentation of Survey Evaluating the Prevalence of Pseudobulbar... May 05 2015
    Avanir Pharmaceuticals Announces Presentation of Survey Evaluating the Prevalence of Pseudobulbar... May 05 2015
    Danny Glover Joins PBA Facts Campaign, to Educate and Build Awareness of Pseudobulbar Affect (PBA),... May 01 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK